NANOBIOTIX 10.13.2014
Paris, France, October 13, 2014 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today the second payment of 1.144 k€ from Bpifrance as part as the funding granted to support the NICE consortium.
Taking into account the development of the Strategic Industrial Innovation (ISI) program and based on the completion of the first milestone "Etape clé 1", Bpifrance has proceed to transfer 1.144 k€ to Nanobiotix. In January 2014, Nanobiotix has received an initial payment of 461 k€ from Bpifrance.
Nanobiotix pursued the non-clinical evaluation phase of NBTXR3 with a view to initiating a clinical trial of NBTXR3 in patients suffering from liver cancer. In this population of patients, the aim of using the product is to increase and prolong patients' survival. This non-clinical evaluation phase should allow Nanobiotix to initiate the clinical development in these cancer diseases in 2015.
In July 2013, Bpifrance granted NICE consortium with a funding of almost €9 million, including €2.8 million directly attributable to Nanobiotix through the Strategic Industrial Innovation (ISI) program which is dedicated to accelerate the clinical and industrial development of the Company's lead product NBTXR3 in liver cancers.
About NICE consortium
The NICE (Nano Innovation for CancEr) consortium consists of five public and private partners with in depth expertise in the field of nanomedicine. Its mission is to build the first French platform to accelerate the development and industrialization of nanomedicine.
In addition to Nanobiotix, the consortium includes Onxeo (ex BioAlliance Pharma) which is developing Livatag®; CEA-Leti, the developer of Lipidots® platform nanoparticles ; DBI, a company specialized in the production of nanomedicine pharmaceutical products and the Institut Galien Paris Sud (University Paris Sud/CNRS), which has an academic-excellence team specialized in nanoparticle research.
The consortium has been accredited by the Medicen Paris Region, a competitive cluster for innovative therapies in Ile-de-France (www.medicen.org).
Disclaimer
This press release contains certain forward-looking statements concerning Nanobiotix and its business. These forward looking statements can be identified by the use of forward looking terminology, including the terms "anticipates", "believes", "estimates", "expects", "intends", "may", "plans", "projects", "should" or "will", or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the forecasts or objectives contained in such forward-looking statements will be confirmed or materialized, which forecasts and objectives are subject to numerous risks including the risks set forth in the 2013 financial annual report of Nanobiotix (a copy of which is available on www.nanobiotix.com) and to developments in general economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country.
|
distributed by
|
